Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MS3Z
|
|||
| Former ID |
DNC002344
|
|||
| Drug Name |
GSK690693
|
|||
| Synonyms |
937174-76-0; GSK690693; GSK-690693; GSK 690693; UNII-GWH480321B; (S)-4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol; CHEBI:90677; GWH480321B; 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol; 4-{2-(4-Amino-1,2,5-Oxadiazol-3-Yl)-1-Ethyl-7-[(3s)-Piperidin-3-Ylmethoxy]-1h-Imidazo[4,5-C]pyridin-4-Yl}-2-Methylbut-3-Yn-2-Ol; J-502225; C21H27N7O3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27N7O3
|
|||
| Canonical SMILES |
CCN1C2=C(C(=NC=C2OCC3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N
|
|||
| InChI |
1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
|
|||
| InChIKey |
KGPGFQWBCSZGEL-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 937174-76-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
26681942, 46135378, 46563378, 56310458, 56374157, 103604655, 125329936, 126626056, 131480689, 134346155, 135597634, 136340166, 136367311, 136920334, 137276025, 138024085, 144116035, 152043775, 152258151, 152344200, 160646988, 160657210, 160832411, 162011394, 162038072, 162205111, 163206398, 163397661, 163642948, 165246676, 172919057, 178101884, 180386997, 189622860, 198975457, 223596973, 223685701, 226649713, 242780965, 251971216, 252160402, 252451445, 252543313
|
|||
| ChEBI ID |
CHEBI:90677
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5196). | |||
| REF 2 | ClinicalTrials.gov (NCT00666081) Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74. | |||
| REF 4 | AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines.Blood.2009 Feb 19;113(8):1723-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.